Endo International PLC (ENDP)
Healthcare | Drug Manufacturers - Other
CEO: Rajiv De Silva
Unfortunately we don't have enough data to calculate Endo International PLC's tickrz rank.
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Endo International PLC's valuation score is comprised of a P/B ratio of 1.2x, a P/S ratio of 0.7x, .
WARREN BUFFETT RANKING
Endo International PLC ranks 492 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors.
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet.
Endo International PLC has a Piotroski F Score of 3 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of -7.69x, a debt/equity ratio of 377% and a Moat Rank of 457 translate to a weak Financial Strength score.
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors.The company has seen its stock fall by -28.5% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 485.
VALUE + YIELD
Endo International PLC currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology.
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. Its -257.5% 5 year annualized EPS growth, 8% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of -6.4% speak to its relatively poor ranking.